Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Thalidomide for Symptomatic Large Granular Lymphocytic Leukemia
NCT06530576Phase 2Recruiting
- Sponsor
- Institute of Hematology and Blood Diseases Hospital
- Start
- Aug 2024
- Primary completion
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of thalidomide in large granular lymphocytic leukemia (LGLL), sponsored by Institute of Hematology and Blood Diseases Hospital. Started Aug 2024; status: recruiting.
02
Drugs
thalidomide
03
Conditions
large granular lymphocytic leukemia (LGLL)
Beyond the preview
Go deeper on NCT06530576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06530576.